ArticleDiabetology & metabolic syndrome2014
Low serum galectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus.
Article in Diabetology & metabolic syndrome, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Serum Galectin-3 in Diabetic Foot Infections: A Case-Control Evaluation of Its Diagnostic and Severity-Grading Utility.Infectious diseases & clinical microbiology · 2026Article
- Elevated serum galectin-3 levels predict the incidence of type 2 diabetes mellitus in a Japanese general population: A 10-year follow-up study.Journal of diabetes investigation · 2026Article
- PerturbingCells · 2026Article
- Maternal Galectins and Glucose Regulation in Pregnancy: Chronic vs. Acute Metabolic Adaptations.Diabetes & metabolism journal · 2026Article
- Cross-Sectional Study of Serum Galectin-3 Levels in Patients with Type 2 Diabetes and Colorectal Polyps.International journal of molecular sciences · 2025Article
- Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk.Journal of medical biochemistry · 2025Article
- Article
- Identification of Risk Factors for Poor Prognosis and Analysis of Their Correlation with Ulcer Severity in Diabetic Foot Patients Undergoing Digital Subtraction Angiography-Guided Intervention.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Galectin 3 rs4644 gene polymorphism is associated with metabolic traits in Serbian adolescent population.Journal of medical biochemistry · 2024Article
- Association between serum Galectin-3 and periodontitis in patients with type 2 diabetes mellitus.Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2023Article
- Urinary Galectin-3 as a Novel Biomarker for the Prediction of Renal Fibrosis and Kidney Disease Progression.Biomedicines · 2022Article
- Metformin: Expanding the Scope of Application-Starting Earlier than Yesterday, Canceling Later.International journal of molecular sciences · 2022Review
- Underestimated Prediabetic Biomarkers: Are We Blind to Their Strategy?Frontiers in endocrinology · 2022Review
- Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview.World journal of diabetes · 2021Review
- Article
- Markers of remodeling in subcutaneous adipose tissue are strongly associated with overweight and insulin sensitivity in healthy non-obese men.Scientific reports · 2020Article
- Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.International journal of molecular sciences · 2018Review
- Inflammation and insulin resistance: New targets encourage new thinking: Galectin-3 and LTBBioEssays : news and reviews in molecular, cellular and developmental biology · 2017Review
- Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis.Oxidative medicine and cellular longevity · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGalectin-3 is a family of soluble beta-galactoside-binding lectins that play many important regulatory roles in inflammation. Galectin-3-deficient mice have been shown to exhibit excess adiposity, hyperglycemia, insulin resistance and systemic inflammation. We investigated the association between serum galectin-3 and insulin resistance in patients with type 2 diabetes using a glucose clamp method.
methodsThis was a cross-sectional study. Twenty patients (mean fasting plasma glucose 7.6 mmol/L, HbA1c 7.2%, BMI 28.1 kg/m(2)) underwent a meal tolerance test and glucose clamp test. Participants were given a test meal and plasma glucose and insulin were measured at 0, 30, 60, 120 and 180 min. The glucose disposal rate was measured during hyperinsulinemic-euglycemic glucose clamps. Serum galectin-3 levels were measured using the enzyme-linked immunosorbent assay method.
resultsThe mean serum galectin-3 level was 5103 pg/ml. Galectin-3 levels correlated significantly with the glucose disposal rate (R = 0.71, P < 0.001), fasting insulin (R = -0.56, P < 0.01), homeostasis model assessment for insulin resistance (R = -0.52, P < 0.05), and the insulin sensitivity index (R = 0.62, P < 0.005). Galectin-3 levels also positively correlated with the serum adiponectin level (R = 0.61, P < 0.05), but not with the high-sensitive C-reactive protein and interleukin-6 and -10.
conclusionsThese results suggest that low levels of serum galectin-3 are associated with insulin resistance in patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.